

Supplementary Information

Synthesis of C3-Halo Substituted Bicyclo[1.1.1]pentylamines via Halosulfoamidation of [1.1.1]Propellane with Sodium Hypohalites and Sulfonamides

Zhi Li,^a Deyou Lan,^a Wei Zhou,^a Jiacheng Li,^a Hui Zhu,^a Chuanming Yu ^a and Xinpeng Jiang ^{*a}

^a College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China

* Corresponding author. E-mail: xjiang@zjut.edu.cn

Table of Contents

1. General information.....	S3
2. Synthesis of substrates 1	S3
3. Preparation of the solution of [1.1.1]propellane in hexane	S3
4. General method	S3
5. Mechanism research.....	S4
5.1 Mechanism research for bromo-sulfonamidation reaction.....	S4
5.2 Possible mechanism of the reaction	S5
5.3 Experimental procedure for the mechanism research for bromo-sulfonamidation reaction.....	S5
5.4 Experimental procedure for the chloro-sulfonamidation reaction.....	S7
6. Gram-scale synthesis of 4a and derivatization of 4q	S8
7. Characterization of products.....	S9
8. References	S17
9. Copies of ¹ H, ¹³ C NMR, and ¹⁹ F NMR spectra of products.....	S18


1. General information

All the commercially available reagents and solvents were used without any purification. The progress of the reactions was monitored by TLC with silica gel plates, and the visualization was carried out under UV light (254 nm). Melting points were determined using a Büchi B-540 capillary melting point apparatus. ^1H NMR, ^{13}C NMR, and ^{19}F NMR spectra were recorded using a Bruker Avance III 400 MHz spectrometers. Chemical shifts of ^1H NMR were reported relative to the solvent signal (CDCl_3 ; $\delta = 7.26$ ppm). Chemical shifts of ^{13}C NMR were reported relative to the solvent signal (CDCl_3 ; $\delta = 77.00$ ppm). High-resolution mass spectra (HRMS) were recorded on Waters SYNAPT G2-S spectrometer. Column chromatography was performed on silica gel (300-400 mesh).

2. Synthesis of substrates 1


The substrates (**1a-1r**, **1t**),¹ and **1s**,² were prepared following the literature procedure, and the NMR data of all these compounds were compared with the corresponding reported data.

3. Preparation of the solution of [1.1.1]propellane in hexane




A solution of *n*-BuLi (32 mL, 80 mmol, 2.0 equiv., 2.5M in hexane) was added dropwise to a suspension of 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane (40 mmol) in anhydrous dibutyl ether (40 mL) under argon at $-78\text{ }^\circ\text{C}$. After the addition was complete, the mixture was allowed to warm to $0\text{ }^\circ\text{C}$ and stirred for 2 h before distillation under vacuum. The concentration can be measured by ^1H -NMR with 1,3,5-trimethoxybenzene as an internal standard (typically concentrations are 0.4-0.7 M).

4. General method



General procedure for the synthesis of **4** (standard conditions A): A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1** (0.2 mmol, 1.0 equiv.) in MeCN (1.0 mL). The sodium hypochlorite **3a** [aq., 10% available chlorine] (0.35 mL, 1.0 mmol, 5.0 equiv.) and [1.1.1]propellane **2** (0.3 mmol, 1.5 equiv.) were added sequentially under stirring. After being stirred for 12 h at $30\text{ }^\circ\text{C}$, the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate to afford the desired product **4**.




Preparation of NaBrO solution: NaOH (6 N, 1.0 mL, 6.0 mmol) was charged in a 25 mL flask equipped with a stir bar and Br₂ (100 μl, 2.0 mmol) was added at 0 °C. After stirring for 10 min, yellow transparent **3b** NaBrO (aq) was obtained. This solution was used in the following synthesis without further purification.³

General procedure for the synthesis of **5** (standard conditions B): A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1** (0.2 mmol, 1.0 equiv.) in DCM (1.0 mL). The sodium hypobromite **3b** (0.55mL, 1.0 mmol, 5 equiv.) and [1.1.1]propellane **2** (0.3 mmol, 1.5 equiv.) were added sequentially at -10 °C under stirring. After being stirred for another 30 min at -10 °C with 23W CFL irradiation, the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate to afford the desired product **5**.


5. Mechanism research

5.1 Mechanism research for bromo-sulfonamidation reaction


When (1-cyclopropylvinyl)-benzene **9**⁴ was used instead of [1.1.1]propellane under standard bromo-sulfonamidation conditions, the addition product **11** could be obtained in 47% yield. At first, we believed that both ionic and radical pathways are involved in this transformation type.



However, the sulfonamide anion generated from NaH with sulfonamide **1a**⁵, reacted with compound **9** for 12h could not obtain the desired product.




Meanwhile, the halogen-lithium exchange reaction of **5a** could afford the sulfonamides **1a** in 56% yield.




Both results indicated that the ionic addition of sulfonamide ion to compound **9** is very difficult, but the reverse ionic reaction – reformation of [1.1.1]propellane – is strongly favored.

One of the reviewers speculated that the observed phenomenon could be attributed to the rapid occurrence of bromine atom abstraction, which is significantly faster than the fragmentation of benzylic radical intermediates. Thus, we conducted a reaction under standard conditions for 30 seconds and


obtained the desired product **5a** in 47% yield. Therefore, we agreed that bromo-sulfonamidation is a very fast radical reaction.




5.2 Possible mechanism of the reaction




5.3 Experimental procedure for the mechanism research for bromo-sulfonamidation reaction




A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (0.2 mmol, 38.2 mg, 1.0 equiv.) in DCM (1.0 mL). The sodium hypobromite **3b** and (1-cyclopropylvinyl)benzene **9** (0.4 mmol, 61.2 mg, 2 equiv.) were added sequentially at -10 °C under stirring. After being stirred for another 30 min at -10 °C with 23W CFL irradiation, the reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 20:1 to afford the product **11** as a white solid (39.6 mg, 47%). M.p.: 89-91 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.67 (d, *J* = 8.0 Hz, 2H), 7.35 – 7.22 (m, 5H), 7.22 – 7.12 (m, 2H), 4.62 (d, *J* = 10.2 Hz, 1H), 4.29 (d, *J* = 10.2 Hz, 1H), 3.13 (s, 3H), 2.42 (s, 3H), 1.86 – 1.77 (m, 1H), 0.72 – 0.52 (m, 1H), 0.52 – 0.39 (m, 1H), 0.37 – 0.23 (m, 1H), -0.11 – -0.30 (m, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 142.86, 138.86, 138.35, 129.05, 127.74, 127.72, 127.56, 70.08, 43.15, 35.05, 21.47, 18.70, 4.36, 2.01. HRMS (ESI) *m/z*: calcd for C₁₉H₂₃BrNO₂S⁺ [M+H]⁺ 408.0627, found: 408.0622.




The sulfonamide salt was prepared according to the literature report.⁵ A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (0.2 mmol, 37.5 mg, 1.0 equiv.) and NaH (0.24, 11.0 mg, 1.2 equiv, 60% in oil). After the tube was evacuated and backfilled with argon three times, anhydrous MeCN(1.0 mL) was added at 0 °C. After stirring for 5 min, the (1-cyclopropylvinyl)benzene **9** (0.4 mmol, 60.0 mg, 2 equiv.) was added at 0 °C under stirring. The resulting mixture was placed in a preheated metal block and stirred at 30 °C for 12 h. After 2.0 mL H₂O quenching reaction, no reaction was monitored by TLC.



A 25 mL dry reaction tube equipped with a stir bar was evacuated and backfilled with argon (three times). Dissolved **5a** (0.24 mmol, 79.9 mg, 1.0 equiv) in anhydrous THF (1.5 mL) was added into a reaction tube, and stirred at -80 °C. Slowly added *tert*-butyl lithium (1.3 M, 0.2 mL, 1.1 equiv) at -80 °C. After the reaction was stirred for 30 min, it was quenched with CH₃OH (2 mL) at -80 °C and then added H₂O (5 mL). The resulting mixture was extracted with ethyl acetate (10 mL × 3). The organic layers were combined, washed with brine, dried over Na₂SO₄ filtered, and then concentrated in a vacuum. The residue was purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 5: 1 to afford **1a** as a white solid (25.1 mg, 56%).



A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (0.2 mmol, 38.0 mg, 1.0 equiv.) in DCM (1.0 mL). The sodium hypobromite **3b** (0.55mL, 1.0 mmol, 5 equiv.) and [1.1.1]propellane **2** (0.3 mmol, 1.5 equiv.) were added sequentially at -10 °C under stirring. After being stirred for another 30 s at -10 °C with 23W CFL irradiation, the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 20:1 to afford the desired product **5a** as a colorless oil (31.5 mg, 47%).



A 10 mL reaction tube equipped with a magnetic stir bar was charged with *N*-bromo-*N*,4-dimethylbenzenesulfonamide **1a-Br**⁶ (0.2 mmol, 53.0 mg, 1.0 equiv.) in DCM (1.0 mL). The [1.1.1]propellane **2** (0.3mmol, 1.5 equiv.) was added at -10 °C under stirring. After being stirred for another 30 min at -10 °C with 23W CFL irradiation, the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 10:1 to afford the desired product **5a** as a colorless oil (31.8 mg, 48%).




A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (0.2 mmol, 37.5 mg, 1.0 equiv.) in DCM (1.0 mL). The sodium hypobromite **3b** (0.55 mL, 1.0 mmol, 5.0 equiv.), TEMPO (0.4 mmol, 65.2mg, 2.0 equiv.) and [1.1.1]propellane **2** (0.3 mmol, 1.5 equiv.) were added sequentially at -10 °C under stirring. After being stirred for another 30 min at -10 °C with 23W CFL irradiation, only trace amount of product was detected by TLC analysis.


5.4 Experimental procedure for the chloro-sulfonamidation reaction



A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (0.2 mmol, 37.0 mg, 1.0 equiv.) in MeCN (1.0 mL). The sodium hypochlorite **3a** [10% available chlorine] (0.35mL, 1.0 mmol, 5.0 equiv.), TEMPO (0.4 mmol, 62.5 mg, 2.0 equiv.) and [1.1.1]propellane **2** (0.3 mmol, 1.5 equiv.) were added sequentially under stirring. After being stirred for 12 h at 30 °C, only a trace amount of product was detected by TLC analysis.



A 10 mL reaction tube equipped with a magnetic stir bar was charged with *N*-chloro-*N*,4-dimethylbenzenesulfonamide **1a-Cl**⁷ (0.2 mmol, 46.2 mg, 1.0 equiv.), **2** (0.3mmol, 1.5 equiv.), and MeCN (1.0 mL). After being stirred for 12 h at 30 °C, the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 10:1 to afford the desired product **4a** as a colorless oil (48.9 mg, 81%).



A 10 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (0.2 mmol, 38.1 mg, 1.0 equiv.) in MeCN (1.0 mL). The sodium hypochlorite **3a** [10% available chlorine] (0.35mL, 1.0 mmol, 5.0 equiv.) and (1-cyclopropylvinyl)benzene **9** (0.4 mmol, 59.8 mg, 2 equiv.) were added sequentially under stirring. After being stirred for 12 h at 30 °C, the reaction mixture was evaporated and then purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 20:1 to afford the product **10** as a colorless oil (7.5 mg, 10%). After the reaction, 61% of substrate **1a** was also recovered. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.69 (d, *J* = 8.6 Hz, 2H), 7.43 (d, *J* = 6.8 Hz, 2H), 7.39 – 7.24 (m, 5H), 5.97 (t, *J* = 7.4 Hz, 1H), 4.45 (s, 2H), 3.19 (t, *J* = 7.4 Hz, 2H), 2.80 (s, 3H), 2.63 – 2.52 (m, 2H), 2.43 (s, 3H).


^{13}C NMR (100 MHz, Chloroform-*d*) δ 143.40, 139.94, 138.21, 134.66, 130.12, 129.71, 128.52, 127.67, 127.39, 125.96, 49.51, 41.19, 35.09, 27.54, 21.50. HRMS (ESI) m/z : calcd for $\text{C}_{19}\text{H}_{23}\text{ClNO}_2\text{S}^+$ $[\text{M}+\text{H}]^+$ 364.1133, found: 364.1136.

6. Gram-scale synthesis of 4a and derivatization of 4q

1) Gram-scale synthesis of 4a


A 100 mL reaction tube equipped with a magnetic stir bar was charged with **1a** (5 mmol, 926.8 mg, 1.0 equiv.) in MeCN (25 mL). The sodium hypochlorite **3a** [10% available chlorine] (8.9 mL, 25 mmol, 5.0 equiv.) and [1.1.1]propellane **2** (7.5 mmol, 1.5 equiv.) was added sequentially at 0 °C under stirring. The mixture was stirred for 12 h at 30 °C. After the reaction was complete as monitored by TLC, it was added with H₂O (10 mL) at room temperature, and then extracted with ethyl acetate (30 mL \times 3). The organic layers were combined, washed with brine, dried over Na₂SO₄ filtered, and then concentrated in a vacuum. The residue was purified by flash chromatography on silica gel with petroleum ether/ethyl acetate to afford the desired product **4a** as a colorless oil (1.297 g, 91 %).

2) Synthesis of *N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-(2,3-dihydroxypropyl)-4-methylbenzenesulfonamide **6**⁸



To a 25 mL Schlenk tube equipped with a stir bar were added **4q** (0.22 mmol, 69.7 mg, 1.0 equiv.), NaIO₄ (0.44 mmol, 93.9 mg, 2.0 eq.) and RuCl₃ (0.0077 mmol, 3.3 mg, 3.5 mol %). After the tube was evacuated and backfilled with argon three times, degassed MeCN (6.0 mL) and H₂O (1.0 mL) were added. After being stirred for 16 h at 30 °C, the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated and then purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate = 2:1) to give **6** as a colorless oil (31.6 mg, 41%); ^1H NMR (400 MHz, Chloroform-*d*) δ 7.67 (d, J = 7.4 Hz, 2H), 7.31 (d, J = 7.8 Hz, 2H), 3.87 – 3.76 (m, 1H), 3.72 (s, 2H), 3.39 (dd, J = 14.8, 6.1 Hz, 1H), 3.23 (dd, J = 14.8, 6.9 Hz, 1H), 2.43 (s, 3H), 2.27 (s, 6H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 144.21, 136.46, 129.91, 127.16, 70.48, 63.11, 58.73, 50.14, 49.61, 46.29, 21.53. HRMS (ESI) m/z : calcd for $\text{C}_{15}\text{H}_{21}\text{ClNO}_4\text{S}^+$ $[\text{M}+\text{H}]^+$ 346.0874, found: 346.0877.


3) Synthesis of methyl (*E*)-4-((*N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methylphenyl)sulfonamido)but-2-enoate **7**⁹



To a 10 mL reaction tube equipped with a stir bar were added **4q** (0.2 mmol, 63.4 mg, 1.0 equiv.),

Grubbs II catalyst (0.004mmol, 3.8 mg, 2 mol %). After the tube was evacuated and backfilled with argon three times, methyl acrylate (90 μ L, 1.0 mmol, 5.0 equiv.) and anhydrous DCM (2.0 mL) was added. After the reaction mixture stirring at 45 °C for 24 h, another 2 mol % of Grubbs II catalyst (0.004mmol, 3.4 mg, 2 mol %) was added. After the reaction mixture stirring for another 24 h, the reaction mixture was evaporated and then purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate 10:1) to give **7** as a white solid (48.9 mg, 65 %); M.p.: 84-86 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.65 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 7.6 Hz, 2H), 6.95-9.73 (m, 1H), 6.01 (d, *J* = 18.0, 1H), 4.07-3.98 (m, 2H), 3.73 (s, 3H), 2.42 (s, 3H), 2.26 (s, 6H). ¹³C NMR (100 MHz, Chloroform-d) δ 165.98, 144.01, 143.75, 137.06, 129.81, 127.10, 122.73, 58.86, 51.68, 49.25, 48.64, 46.15, 21.49. HRMS (ESI) *m/z*: calcd for C₁₇H₂₁ClNO₄S⁺ [M+H]⁺ 370.0874, found: 370.0872.


4) Synthesis of *N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methylbenzenesulfonamide **8**¹⁰



A 10 mL reaction tube equipped with a stir bar was evacuated and backfilled with argon (three times). The Pd(PPh₃)₄ (0.01 mmol, 11.8 mg, 5 mol %), THF(3.0 mL), vinylmagnesium bromide (1.0 M solution in THF, 0.8 mmol, 4.0 eq.), and **4q** (0.2 mmol, 63.0 mg, 1.0 eq.) were then added at 0 °C under stirring. The resulting mixture was placed in a preheated metal block and stirred at 30 °C for 24 h. After the reaction was complete as monitored by TLC analysis, it was quenched with saturated NaHCO₃ solution (5 mL) at room temperature and then extracted with ether (10 mL \times 3). The organic layers were combined, washed with brine, dried over Na₂SO₄ filtered, and then concentrated in a vacuum. The residue was purified by flash chromatography on silica gel with petroleum ether/ethyl acetate = 10: 1 to afford **8** as a yellow solid (29.8 mg, 54%). M.p.: 142-144 °C; ¹H NMR (400 MHz, Chloroform-d) δ 7.75 (d, *J* = 8.2 Hz, 2H), 7.31 (d, *J* = 7.6 Hz, 2H), 5.79 (s, 1H), 2.44 (s, 3H), 2.15 (s, 6H). ¹³C NMR (100 MHz, Chloroform-d) δ 143.96, 137.28, 129.76, 127.23, 58.77, 46.27, 44.36, 21.55. HRMS (ESI) *m/z*: calcd for C₁₂H₁₅ClNO₂S⁺ [M+H]⁺ 272.0507, found: 272.0500.


7. Characterization of products

N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*,4-dimethylbenzenesulfonamide (**4a**)¹¹




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **4a** was isolated as a colorless oil (51.0 mg, 88 %, **4a:4a-S** = 96:4); ¹H NMR (400 MHz, Chloroform-d) δ 7.66 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 2.81 (s, 3H), 2.42 (s, 3H), 2.25 (s, 6H). ¹³C NMR (100 MHz, Chloroform-d) δ 143.76, 135.52, 129.69, 127.33, 57.90, 49.68, 46.26, 34.09, 21.48.

N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylbenzenesulfonamide (**4b**)




Eluent in chromatography: petroleum ether/ ethyl acetate 20:1, **4b** was isolated as a white solid (48.1 mg, 77 %, **4b:4b-S** = 95:5); M.p.: 66-68 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.78 (d, *J* = 7.8 Hz, 2H), 7.63 – 7.56 (m, 1H), 7.56 – 7.48 (m, 2H), 2.83 (s, 3H), 2.25 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 138.51, 132.89, 129.09, 127.24, 57.90, 49.65, 46.21, 34.12. HRMS (ESI) *m/z*: calcd for C₁₂H₁₅ClNO₂S⁺ [M+H]⁺ 272.0507, found: 272.0504.

4-(*tert*-butyl)-*N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylbenzenesulfonamide (**4c**)




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **4c** was isolated as a white solid (55.8 mg, 86 %, **4c:4c-S** = 95:5); M.p.: 96-97 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 (d, *J* = 8.2 Hz, 2H), 7.52 (d, *J* = 8.2 Hz, 2H), 2.83 (s, 3H), 2.26 (s, 6H), 1.34 (s, 9H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 156.77, 135.48, 127.19, 126.05, 57.98, 49.73, 46.31, 35.13, 34.13, 31.04. HRMS (ESI) *m/z*: calcd for C₁₆H₂₃ClNO₂S⁺ [M+H]⁺ 328.1133, found: 328.1134.

N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-[1,1'-biphenyl]-4-sulfonamide (**4d**)




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **4d** was isolated as a white solid (34.4 mg, 50 %); M.p.: 148-149 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.85 (d, *J* = 8.0 Hz, 2H), 7.74 (d, *J* = 8.0 Hz, 2H), 7.62 (d, *J* = 7.6 Hz, 2H), 7.53 – 7.39 (m, 3 H), 2.88 (s, 3H), 2.31 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 145.77, 138.99, 137.23, 129.03, 128.55, 127.83, 127.63, 127.23, 58.05, 49.76, 46.28, 34.13. HRMS (ESI) *m/z*: calcd for C₁₈H₁₉ClNO₂S⁺ [M+H]⁺ 348.0820, found: 348.0826.

N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*,2,4,6-tetramethylbenzenesulfonamide (**4e**)




Eluent in chromatography: petroleum ether/ ethyl acetate 20:1, **4e** was isolated as a white solid (14.4 mg, 23 %, **4e:4e-S** = 97:3); M.p.: 71-73 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 6.94 (s, 2H), 2.75 (s, 3H), 2.57 (s, 6H), 2.30 (s, 3H), 2.26 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 142.86, 140.17, 133.16, 131.95, 57.92, 49.50, 46.45, 32.31, 22.56, 20.98. HRMS (ESI) *m/z*: calcd for C₁₅H₂₁ClNO₂S⁺ [M+H]⁺ 314.0976, found: 314.0975.

3-chloro-*N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-fluoro-*N*-methylbenzenesulfonamide (4f)




Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4f** was isolated as a white solid (47.5 mg, 78 %, **4f:4f-S** = 97:3); M.p.: 95-96 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.89 – 7.83 (m, 1H), 7.73 – 7.66 (m, 1H), 7.30 (t, *J* = 8.4 Hz, 1H), 2.85 (s, 3H), 2.30 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 160.66 (d, *J* = 257.6 Hz), 135.88 (d, *J* = 4.0 Hz), 130.18, 127.71 (d, *J* = 8.4 Hz), 122.54 (d, *J* = 18.8 Hz), 117.46 (d, *J* = 22.4 Hz), 58.11, 49.69, 46.13, 34.16. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -106.70. HRMS (ESI) *m/z*: calcd for C₁₂H₁₃Cl₂FNO₂S⁺ [*M*+*H*]⁺ 324.0023, found: 324.0033.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-3-cyano-*N*-methylbenzenesulfonamide (4g)**




Eluent in chromatography: petroleum ether/ ethyl acetate 5:1, **4g** was isolated as a white solid (27.5 mg, 46 %); M.p.: 92-94 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.06 (s, 1H), 8.02 (d, *J* = 8.0 Hz, 1H), 7.89 (d, *J* = 8.6 Hz, 1H), 7.73 – 7.65 (m, 1H), 2.87 (s, 3H), 2.29 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 140.69, 135.97, 131.13, 130.74, 130.27, 116.96, 113.83, 58.10, 49.62, 46.05, 34.19. HRMS (ESI) *m/z*: calcd for C₁₃H₁₄ClN₂O₂S⁺ [*M*+*H*]⁺ 297.0459, found: 297.0473.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-2-nitrobenzenesulfonamide (4h)**



Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4h** was isolated as a yellow solid (44.3 mg, 69 %, **4h:4h-S** = 96:4); M.p.: 131-133 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.04 (d, *J* = 6.8 Hz, 1H), 7.76 – 7.62 (m, 3H), 2.94 (s, 3H), 2.30 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 147.99, 133.97, 133.42, 131.81, 130.68, 124.27, 58.08, 49.37, 46.23, 34.05. HRMS (ESI) *m/z*: calcd for C₁₂H₁₄ClN₂O₄S⁺ [*M*+*H*]⁺ 317.0357, found: 317.0365.


***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-2,3-dihydrobenzofuran-5-sulfonamide (4i)**



Eluent in chromatography: petroleum ether/ ethyl acetate 5:1, **4i** was isolated as a white solid (52.0 mg, 85 %, **4i:4i-S** = 95:5); M.p.: 117-118 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.62 – 7.49 (m, 2H), 6.83 (d, *J* = 8.2 Hz, 1H), 4.68 (t, *J* = 8.8 Hz, 2H), 3.27 (t, *J* = 8.8 Hz, 2H), 2.79 (s, 3H), 2.26 (s, 6H). ¹³C NMR


(100 MHz, Chloroform-d) δ 163.94, 129.88, 128.93, 128.34, 124.55, 109.46, 72.25, 57.92, 49.74, 46.31, 34.07, 28.97. HRMS (ESI) m/z : calcd for $C_{14}H_{17}ClNO_3S^+$ $[M+H]^+$ 314.0612, found: 314.0610.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylnaphthalene-2-sulfonamide (4j)**




Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4j** was isolated as a white solid (48.4 mg, 75 %, **4j:4j-S** = 95:5); M.p.: 89-90 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.36 (s, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.93 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), δ 7.71 – 7.60 (m, 2H), 2.90 (s, 3H), 2.29 (s, 6H). ^{13}C NMR (100 MHz, Chloroform-d) δ 135.64, 134.86, 132.15, 129.40, 129.21, 129.00, 128.85, 127.94, 127.70, 122.42, 58.10, 49.79, 46.30, 34.24. HRMS (ESI) m/z : calcd for $C_{16}H_{17}ClNO_2S^+$ $[M+H]^+$ 322.0663, found: 322.0666.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)thiophene-2-sulfonamide (4k)**




Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4k** was isolated as a colorless oil (51.0 mg, 84 %, **4k:4k-S** = 95:5); 1H NMR (400 MHz, Chloroform-d) δ 7.62 (dd, J = 5.0, 1.4 Hz, 1H), 7.56 (dd, J = 3.8, 1.4 Hz, 1H), 7.11 (dd, J = 5.0, 3.6 Hz, 1H), 2.84 (s, 3H), 2.31 (s, 6H). ^{13}C NMR (100 MHz, Chloroform-d) δ 138.76, 132.53, 132.16, 127.45, 57.94, 49.76, 46.19, 34.15. HRMS (ESI) m/z : calcd for $C_{10}H_{13}ClNO_2S_2^+$ $[M+H]^+$ 278.0071, found: 278.0070.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylpyridine-3-sulfonamide (4l)**




Eluent in chromatography: petroleum ether/ ethyl acetate 3:1, **4l** was isolated as a colorless oil (39.6 mg, 70 %, **4l:4l-S** = 96:4); 1H NMR (400 MHz, Chloroform-d) δ 9.00 (s, 1H), 8.82 (d, J = 4.8 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.53 – 7.41 (m, 1H), 2.87 (s, 3H), 2.29 (s, 6H). ^{13}C NMR (100 MHz, Chloroform-d) δ 153.40, 148.07, 135.39, 134.88, 123.74, 58.06, 49.62, 46.09, 34.06. HRMS (ESI) m/z : calcd for $C_{11}H_{14}ClN_2O_2S^+$ $[M+H]^+$ 273.0459, found: 273.0467.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyldimethylaminesulfonamide (4m)**




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **4m** was isolated as a colorless oil (24.3 mg, 46 %, **4m:4m-S** = 96:4); 1H NMR (400 MHz, Chloroform-d) δ 2.80 (s, 3H), 2.77 (s, 6H), 2.38 (s, 6H). ^{13}C NMR (100 MHz, Chloroform-d) δ 58.08, 50.14, 46.32, 37.65, 34.50. HRMS (ESI) m/z : calcd for $C_8H_{16}ClN_2O_2S^+$ $[M+H]^+$ 239.0616, found: 239.0612.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylcyclopropanesulfonamide (4n)**




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **4n** was isolated as a white solid (21.2 mg, 41 %); M.p.: 69-71 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 2.87 (s, 3H), 2.42 (s, 6H), 2.29 – 2.18 (m, 1H), 1.22 – 1.14 (m, 2H), 1.00 (d, *J* = 5.9 Hz, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 58.45, 49.85, 46.27, 34.26, 28.11, 5.03. HRMS (ESI) *m/z*: calcd for C₉H₁₅ClNO₂S⁺ [M+H]⁺ 236.0507, found: 236.0501.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-ethyl-4-methylbenzenesulfonamide (4o)**




Eluent in chromatography: petroleum ether/ ethyl acetate 20:1, **4o** was isolated as a white solid (40.4 mg, 68 %, **4o:4o-S** = 97:3); M.p.: 53-55 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 (d, *J* = 8.4 Hz, 2H), 7.28 (d, *J* = 8.0 Hz, 2H), 3.32 (q, *J* = 7.0 Hz, 2H), 2.41 (s, 3H), 2.30 (s, 6H), 1.21 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 143.44, 137.80, 129.63, 126.98, 59.05, 49.00, 46.36, 43.25, 21.46, 16.12. HRMS (ESI) *m/z*: calcd for C₁₄H₁₉ClNO₂S⁺ [M+H]⁺ 300.0820, found: 300.0827.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methyl-*N*-pentylbenzenesulfonamide (4p)**




Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4p** was isolated as a colorless oil (32 mg, 45%, **4p:4p-S** = 98:2); ¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.2 Hz, 2H), 3.28 – 3.15 (m, 2H), 2.42 (s, 3H), 2.28 (s, 6H), 1.64 – 1.55 (m, 2H), 1.35 – 1.24 (m, 4H), 0.90 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 143.42, 137.97, 129.62, 127.07, 59.07, 49.28, 48.56, 46.45, 30.17, 28.76, 22.24, 21.45, 13.90. HRMS (ESI) *m/z*: calcd for C₁₇H₂₅ClNO₂S⁺ [M+H]⁺ 342.1289, found: 342.1299.

***N*-allyl-*N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methylbenzenesulfonamide (4q)**




Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4q** was isolated as a colorless oil (33 mg, 52%, **4q:4q-S** = 95:5); ¹H NMR (400 MHz, Chloroform-*d*) δ 7.67 (d, *J* = 8.0 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), δ 5.86 – 5.72 (m, 1H), 5.29 – 5.12 (m, 2H), 3.91 (d, *J* = 5.0 Hz, 2H), 2.42 (s, 3H), 2.29 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 143.71, 137.72, 134.55, 129.76, 127.21, 117.74, 59.16, 50.79, 49.38, 46.53, 21.56. HRMS (ESI) *m/z*: calcd for C₁₅H₁₉ClNO₂S⁺ [M+H]⁺ 312.0820, found: 312.0825.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (4r)**




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **4r** was isolated as a yellow oil (37.2 mg, 58 %); ¹H NMR (400 MHz, Chloroform-*d*) δ 7.75 (d, *J* = 8.0 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 4.16 (s, 2H), 2.42 (s, 3H), 2.37 (s, 6H), 2.19 (s, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 143.98, 136.78, 129.52, 127.70, 78.49, 73.64, 59.01, 49.00, 46.20, 37.22, 21.54. HRMS (ESI) *m/z*: calcd for C₁₅H₁₇ClNO₂S⁺ [M+H]⁺ 310.0663, found: 310.0666.

2-(3-chlorobicyclo[1.1.1]pentan-1-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (4s)




Eluent in chromatography: petroleum ether/ ethyl acetate 5:1, **4s** was isolated as a white solid (18.8 mg, 35 %, **4s:4s-S** = 95:5); M.p.: 151-152 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.77 (d, *J* = 7.8 Hz, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.53 (t, *J* = 7.6 Hz, 1H), 7.39 (d, *J* = 7.6 Hz, 1H), 4.35 (s, 2H), 2.58 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 135.09, 132.93, 132.50, 129.34, 124.49, 121.39, 57.90, 48.74, 46.74, 45.98. HRMS (ESI) *m/z*: calcd for C₁₂H₁₃ClNO₂S⁺ [M+H]⁺ 270.0350, found: 270.0345.

***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-1-(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-*N*-methylmethanesulfonamide (4t)**



Eluent in chromatography: petroleum ether/ethyl acetate 10:1, **4t** was isolated as a white solid (34 mg, 48%); M.p.: 84-85 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 3.32 (d, *J* = 14.4 Hz, 1H), 2.87 (s, 3H), 2.75 (d, *J* = 14.4 Hz, 1H), 2.55 – 2.47 (m, 1H), 2.45 (s, 6H), 2.37 (dt, *J* = 18.4, 4.2 Hz, 1H), 2.12 – 1.98 (m, 2H), 1.93 (d, *J* = 18.4 Hz, 1H), δ 1.67 – 1.57 (m, 1H), 1.47 – 1.37 (m, 1H), 1.12 (s, 3H), 0.87 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 214.89, 58.37, 49.82, 47.74, 47.17, 46.32, 42.82, 42.52, 33.84, 26.85, 25.17, 20.02, 19.76. HRMS (ESI) *m/z*: calcd for C₁₆H₂₅ClNO₃S⁺ [M+H]⁺ 346.1238, found: 346.1240.


***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*,4-dimethylbenzenesulfonamide (5a)**



Eluent in chromatography: petroleum ether/ethyl acetate 15:1, **5a** was isolated as a colorless oil (47.6 mg, 70%, **5a:5a-S** = 98:2); ¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 2.81 (s, 3H), 2.44 (s, 3H), 2.32 (s, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 143.81,


135.62, 129.74, 127.40, 59.09, 52.10, 34.01, 33.06, 21.54. HRMS (ESI) m/z : calcd for $C_{13}H_{17}BrNO_2S^+$ $[M+H]^+$ 330.0158, found: 330.0161.

***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-[1,1'-biphenyl]-4-sulfonamide (5b)**




Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **5b** was isolated as a white solid (29.5 mg, 37 %); M.p.: 135-136 °C; 1H NMR (400 MHz, Chloroform- d) δ 7.88 – 7.82 (m, 2H), 7.77 – 7.70 (m, 2H), 7.64 – 7.59 (m, 2H), 7.53 – 7.39 (m, 3H), 2.87 (s, 3H), 2.37 (s, 6H). ^{13}C NMR (100 MHz, Chloroform- d) δ 145.83, 139.00, 137.11, 129.06, 128.59, 127.86, 127.68, 127.27, 59.15, 52.11, 34.06, 33.00. HRMS (ESI) m/z : calcd for $C_{18}H_{19}BrNO_2S^+$ $[M+H]^+$ 392.0314, found: 392.0317.

***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-4-(tert-butyl)-*N*-methylbenzenesulfonamide (5c)**




Eluent in chromatography: petroleum ether/ ethyl acetate 20:1, **5c** was isolated as a white solid (42.5 mg, 57 %); M.p.: 103-105 °C; 1H NMR (400 MHz, Chloroform- d) δ 7.72 – 7.66 (m, 2H), 7.54 – 7.49 (m, 2H), 2.82 (s, 3H), 2.33 (s, 6H), 1.34 (s, 9H). ^{13}C NMR (100 MHz, Chloroform- d) δ 156.80, 135.49, 127.20, 126.08, 59.12, 52.10, 35.15, 34.01, 33.10, 31.05. HRMS (ESI) m/z : calcd for $C_{16}H_{23}BrNO_2S^+$ $[M+H]^+$ 372.0627, found: 372.0623.

***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*,2,4,6-tetramethylbenzenesulfonamide (5d)**



Eluent in chromatography: petroleum ether/ ethyl acetate 20:1, **5d** was isolated as a yellow oli (21.9 mg, 30 %); 1H NMR (400 MHz, Chloroform- d) δ 6.94 (s, 2H), 2.74 (s, 3H), 2.57 (s, 6H), 2.33 (s, 6H), 2.30 (s, 3H). ^{13}C NMR (100 MHz, Chloroform- d) δ 142.87, 140.17, 133.14, 131.96, 59.05, 51.88, 33.24, 32.18, 22.57, 20.99. HRMS (ESI) m/z : calcd for $C_{15}H_{21}BrNO_2S^+$ $[M+H]^+$ 358.0471, found: 358.0465.


***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methylnaphthalene-2-sulfonamide (5e)**



Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **5e** was isolated as a white solid (28.6 mg, 38 %); M.p.: 86-88 °C; 1H NMR (400 MHz, Chloroform- d) δ 8.36 (d, J = 1.4 Hz, 1H), 8.02 – 7.95 (m, 2H), 7.93 (dd, J = 8.0, 1.4 Hz, 1H), 7.75 (dd, J = 8.6, 1.8 Hz, 1H), 7.71 – 7.60 (m, 2H), 2.89 (s, 3H), 2.34 (s, 6H). ^{13}C NMR (100 MHz, Chloroform- d) δ 135.59, 134.84, 132.12, 129.40, 129.20, 129.00, 128.82,


127.93, 127.70, 122.38, 59.20, 52.11, 34.11, 32.99. HRMS (ESI) m/z : calcd for $C_{16}H_{17}BrNO_2S^+$ $[M+H]^+$ 366.0158, found: 366.0151.

***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-2,3-dihydrobenzofuran-5-sulfonamide (5f)**




Eluent in chromatography: petroleum ether/ ethyl acetate 5:1, **5f** was isolated as a white solid (49.8 mg, 67 %, **5f:5f-S** = 98:2); M.p.: 115-117 °C; 1H NMR (400 MHz, Chloroform- d) δ 7.61 – 7.53 (m, 2H), 6.84 (d, J = 8.4 Hz, 1H), 4.68 (t, J = 8.8 Hz, 2H), 3.27 (t, J = 8.8 Hz, 2H), 2.78 (s, 3H), 2.32 (s, 6H). ^{13}C NMR (100 MHz, Chloroform- d) δ 163.97, 129.94, 128.97, 128.35, 124.57, 109.51, 72.28, 59.08, 52.14, 33.97, 33.13, 29.01. HRMS (ESI) m/z : calcd for $C_{14}H_{17}BrNO_3S^+$ $[M+H]^+$ 358.0107, found: 358.0103.

***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methylthiophene-2-sulfonamide (5g)**



Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **5g** was isolated as a yellow oli (15.4 mg, 23 %); 1H NMR (400 MHz, Chloroform- d) δ 7.62 (dd, J = 5.0, 1.2 Hz, 1H), 7.57 (dd, J = 3.8, 1.2 Hz, 1H), 7.13 (dd, J = 5.0, 3.6 Hz, 1H), 2.85 (s, 3H), 2.38 (s, 6H). ^{13}C NMR (100 MHz, Chloroform- d) δ 138.80, 132.54, 132.16, 127.46, 59.06, 52.11, 34.04, 32.86. HRMS (ESI) m/z : calcd for $C_{10}H_{13}BrNO_2S_2^+$ $[M+H]^+$ 321.9566, found: 321.9564.

***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-ethyl-4-methylbenzenesulfonamide (5h)**





Eluent in chromatography: petroleum ether/ ethyl acetate 10:1, **5h** was isolated as a yellow solid (39.8 mg, 57 %); M.p.: 74-75 °C; 1H NMR (400 MHz, Chloroform- d) δ 7.66 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 3.31 (q, J = 7.0 Hz, 2H), 2.42 (s, 3H), 2.36 (s, 6H), 1.21 (t, J = 7.2 Hz, 3H). ^{13}C NMR (100 MHz, Chloroform- d) δ 143.49, 137.86, 129.67, 127.02, 60.22, 51.42, 43.16, 33.17, 21.51, 16.18. HRMS (ESI) m/z : calcd for $C_{14}H_{19}BrNO_2S^+$ $[M+H]^+$ 344.0314, found: 344.0309.

8. References



1. N. Radhoff and A. Studer, *Nat. Commun.*, 2022, **13**, 3083.
2. R. Joseph, C. Murray and P. Garner, *Org. Lett.*, 2014, **16**, 1550-1553.
3. H. Sun, H. Shang and B. Cui, *ACS Catal.*, 2022, **12**, 7046-7053.
4. P. Bellotti, H.-M. Huang, T. Faber, R. Laskar and F. Glorius, *Chem. Sci.*, 2022, **13**, 7855-7862.
5. A. F. J. van den Boom and H. Zuilhof, *Org. Lett.*, 2023, **25**, 788-793.
6. M.-M. Wang and J. Waser, *Angew. Chem. Int. Ed.*, 2019, **58**, 13880-13884.
7. J.-J. Feng and M. Oestreich, *Org. Lett.*, 2018, **20**, 4273-4276.
8. H. Azizollahi, M. Pérez-Gómez, V. P. Mehta and J.-A. García-López, *Adv. Synth. Catal.*, 2020, **362**, 1899-1904.
9. H. D. Pickford, J. Nugent, B. Owen, J. J. Mousseau, R. C. Smith and E. A. Anderson, *J. Am. Chem. Soc.*, 2021, **143**, 9729-9736.
10. G.-J. Jiang, X.-F. Fu, Q. Li and Z.-X. Yu, *Org. Lett.*, 2012, **14**, 692-695.
11. J. H. Kim, A. Ruffoni, Y. S. S. Al-Faiyz, N. S. Sheikh and D. Leonori, *Angew. Chem. Int. Ed.*, 2020, **59**, 8225-8231.

9. Copies of ^1H , ^{13}C NMR, and ^{19}F NMR spectra of products



N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*,4-dimethylbenzenesulfonamide (4a)





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylbenzenesulfonamide (4b)**





4-(tert-butyl)-N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-N-methylbenzenesulfonamide (4c)





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-[1,1'-biphenyl]-4-sulfonamide (4d)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*,2,4,6-tetramethylbenzenesulfonamide (4e)**





3-chloro-N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-fluorobenzenesulfonamide (4f)





--106.70





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-3-cyano-*N*-methylbenzenesulfonamide (4g)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-2-nitrobenzenesulfonamide (4h)**





147.99, 133.97, 133.42, 131.81, 130.68, 124.27, 77.32, 77.00, 76.68, 58.08, 49.37, 46.23, 34.05





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-2,3-dihydrobenzofuran-5-sulfonamide (4i)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylnaphthalene-2-sulfonamide (4j)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)thiophene-2-sulfonamide (4k)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylpyridine-3-sulfonamide (4l)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylmethanesulfonamide (4m)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-methylcyclopropanesulfonamide (4n)**







***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-ethyl-4-methylbenzenesulfonamide (4o)**







***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methyl-*N*-pentylbenzenesulfonamide (4p)**







N-allyl-N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methylbenzenesulfonamide (4q)





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (4r)**





2-(3-chlorobicyclo[1.1.1]pentan-1-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide (4s)





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-1-(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-*N*-methylmethanesulfonamide (4t)**







***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*,4-dimethylbenzenesulfonamide (5a)**





***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-[1,1'-biphenyl]-4-sulfonamide (5b)**







***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-4-(*tert*-butyl)-*N*-methylbenzenesulfonamide (5c)**





***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*,2,4,6-tetramethylbenzenesulfonamide (5d)**







***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methylnaphthalene-2-sulfonamide (5e)**





***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methyl-2,3-dihydrobenzofuran-5-sulfonamide (5f)**





***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-methylthiophene-2-sulfonamide (5g)**



***N*-(3-bromobicyclo[1.1.1]pentan-1-yl)-*N*-ethyl-4-methylbenzenesulfonamide (5h)**





***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-*N*-(2,3-dihydroxypropyl)-4-methylbenzenesulfonamide (6)**





methyl (E)-4-((N-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methylphenyl)sulfonamido)but-2-enoate



(7)



***N*-(3-chlorobicyclo[1.1.1]pentan-1-yl)-4-methylbenzenesulfonamide (8)**



(E)-N-(5-chloro-2-phenylpent-2-en-1-yl)-N,4-dimethylbenzenesulfonamide (11)



(Z)-N-(5-bromo-2-phenylpent-1-en-1-yl)-N,4-dimethylbenzenesulfonamide (12)

